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Statin therapy, LDL cholesterol, C-reactive protein, and coronary
artery disease
Nissen SE, Tuzcu EN, Schoenhagen P, et al. N Engl J Med 2005;352:29-38.
Conclusion: The reduced rate of the progression of atherosclerosis
with intensive statin therapy compared with moderate statin therapy in
patients with coronary disease is related to reductions in levels of C-reactive
protein (CRP) and atherogenic proteins.
Summary: The authors sought to determine whether evidence from
recent trials that demonstrates better outcomes with intensive versus moderate
statin therapy (NEngl JMed2004;350:1495-504 and JAMA2004; 291:1071-
80) is related to reductions in levels of CRP as well as reductions in levels of
atherogenic proteins. Patients were randomly allocated to moderate treatment
with 40 mg of oral pravastatin per day or intensive treatment with 80 mg of
atorvastatin per day. All patients had angiographically documented coronary
disease and were followed with intravascular ultrasound initially and at 18
months to measure progression of atherosclerosis. CRP and lipoprotein levels
were measured at baseline and follow-up.
The mean low-density lipoprotein (LDL) cholesterol level decreased
from 150.2mg/dL at baseline to 94.5 mg/dL in the group as a whole at 18
months (P .001). CRP levels also decreased from 2.9 to 2.3 mg/dL (P
.001). There was a weak correlation between the reduction in LDL choles-
terol levels and CRP levels (r 0.13, P .005). This reduction held for the
group as a whole but was not significant in either treatment group alone.
With univariant analysis, percent changes in CRP, LDL cholesterol, apoli-
poprotein B-100, and nonhigh density lipoprotein cholesterol were related
to rates of progression of atherosclerosis. Adjusting for the reduction in lipid
levels, decreases in CRPwere independently and significantly correlated with
rates of progression of atherosclerosis. Those patients with reductions in
both CRP and LDL cholesterol greater than the median had significantly
slower rates of progression than patients with reductions of both CRP and
LDL cholesterol that were less than the median (P  .001).
Comment: This is another bit of evidence that statin-mediated reduc-
tions in LDL cholesterol and CRP are, for the most part, unrelated.
Reductions in levels of atherogenic proteins in this study were not closely
correlated with reductions in CRP levels. This study, along with a similar
study in the same issue of theNew England Journal of Medicine (2005;352:
20-8), suggests monitoring of both CRP and atherogenic protein levels in
patients on statin therapy.
Effectiveness and safety of dialysis vascular access procedures per-
formed by interventional nephrologists
Beathard GA, Litchfield T, and PhysicianOperators Forum of RMS Lifeline,
Inc. Kidney Int 2004:66:1622-32.
Conclusion: Appropriately trained interventional nephrologists can
performed basic procedures essential to the maintenance of hemodialysis
access.
Summary: An interventional nephrologist performs interventional
procedures pertinent to management of patients with renal disease. These
procedures have traditionally included renal biopsy and insertion of tempo-
rary dialysis venous catheters. Some interventional nephrologists are now
performing dialysis vascular access maintenance procedures. These include
tunneled catheter placement and exchange, angioplasty, and thrombolysis
procedures on synthetic grafts and native fistulas. The authors analyzed data
on six hemodialysis access maintenance procedures performed by interven-
tional nephrologists. These included angioplasty of arteriovenous fistulas
(AVF-PTA), angioplasties of synthetic grafts (graft-PTA), thrombectomy of
arteriovenous fistulas (AVF declot), thrombectomy of synthetic grafts (Graft
declot), placement of tunneled dialysis catheters (TDC), and placement and
tunneled dialysis catheter exchange (TDC exchange). Data were derived
from 11 free-standing outpatient facilities in the United States. All but one
were private practice nephrology groups. A total of twenty-nine interven-
tional nephrologists were involved in performance of the procedures.
A total of 14,067 cases were performed, and 96.18% were successful.
The minor complication rate was 3.26% and primarily included minor
bleeding and reactions to medications. The major complication rate was
0.82% and included significant hematomas, pneumothorax, peripheral ar-
tery embolism, and two deaths within 30 days of performance of a proce-
dure. Cases performed in each category with success rates were as follows:
TDC placement–1,765 cases, 98.24% successful; TDC exchange–2,262
cases, 98.36% successful; AVF-PTA-1-561 cases, 96.58% successful; graft-
PTA–3,560 cases, 98.06% successful; AVF declot–228 cases, 78.10% suc-
cessful; graft declot–4,671 cases, 93.08% successful.
Comment: These cases were performed in an angiography suite. None
involved open surgical procedures with the creation of arteriovenous fistulas
or placement of synthetic grafts or surgical revisions of fistulas or grafts. The
report is very simplistic in that long-term results were not considered. No
life-table analysis is presented. However, it does appear nonsurgically trained
and nonradiologically trained physicians can learn catheter-based proce-
dures pertinent to maintenance of hemodialysis access.
Accelerated enlargement of experimental abdominal aortic aneurysms
in a mouse model of chronic cigarette smoke exposure.
Buckley C,Wyble CW, BorhaniM, et al. J AmColl Surg 2004;199896-903.
Conclusion: In a model of experimental abdominal aortic aneurysms
(AAAs), short-term exposure to cigarette smoke did not effect development
of the aneurysm. Chronic smoke exposure was associated with a significant
increase in late aneurysm dilatation.
Summary: The biologic mechanisms linking cigarette smoke and
emphysema with AAA are unknown. The study was designed to determine if
cigarette smoking enhances the growth of an experimental AAA. Experi-
mental AAAs were created with elastase perfusion of the abdominal aorta in
129/SdEb mice. The experimental mice were subject to chronic cigarette
smoking for 2 weeks, followed by elastase perfusion of the abdominal aorta.
Smoking was then continued for either 2 or 12 weeks. Twenty-nine non-
smoking control mice also under went elastase perfusion and follow-up
evaluation at the same time intervals. Aortic diameters were measured to
determine increases in aortic diameter (AD). An abdominal aortic aneu-
rysm was defined as a AD 100%.
The experimental groups did not differ with regard to preperfusion and
immediate postperfusion ADs. In both smoking and nonsmoking controls,
aneurysm dilatation was present 2 weeks after elastase perfusion, with no
significant difference in the final AD. AAAs developed in all animals by 12
weeks after elastase perfusion. Aorta dilatation was 50% greater in smoking
mice compared with nonsmoking controls (AD smoking, 204%  23% vs
non smoking, 135%  17%; P  .05).
Comment: This study serves as a first step toward determining how
cigarette smoking may influence the development of aneurysms. It repre-
sents a combination of two well-characterized experimental models, an
elastase-induced model of AAA and a model of cigarette smoke-induced
pulmonary emphysema. The study indicates it is feasible to combine the two
models in a single animal. It may eventually yield clues as to the mechanism
of tobacco-induced aortic degeneration.
Incidence of deep vein thrombosis after varicose vein surgery.
van Rij AM, Chai J, Hill GB, Christie RA. Br J Surg 2004;91:1582-1585.
Conclusions: A measurable incidence of deep vein thrombosis (DVT)
occurs after varicose vein surgery. DVT after varicose vein surgery has
minimal short- and long- term clinical significance.
Summary:This was a prospective study to examine the incidence ofDVT
in patients undergoing varicose vein surgery. Leg veins were examined before
varicose vein surgery by duplex ultrasound scanning in 377 patients. The veins
were reassessed at 2 to 4 weeks after surgery and again at 6 and 12 months.
Patientswere instructed to contact a physician if symptoms consistentwithDVT
occurred before any scheduled follow-up appointment. Subcutaneous heparin
for DVT prophylaxis was used at the discretion of the operating surgeon.
DVT was detected in 20 (5.3%) of the 377 patients. Only eight DVT
were symptomatic, and no patient developed symptoms consistent with
pulmonary embolism. Of the 20 DVT detected, 18 were confined to calf
veins. Subcutaneous heparin as a prophylactic agent prior to varicose vein
surgery did not appear to alter outcome, with 64.7% of patients receiving
prophylaxis, and 5.7% of patients who received prophylaxis developing
DVT. No patient aged 40 years in this study developed a DVT with
varicose vein surgery. Risk factors for DVT with varicose vein surgery were
CEAP classes 5 and 6 and a positive family history of DVT. Obesity and oral
contraceptives were not risk factors for DVT after varicose vein surgery.
None of the thrombi found in this study progressed, and half resolved within
1 year, without evidence of venous reflux in the deep veins.
Comment: Prophylaxis for venous thrombosis in patients undergoing
varicose vein surgery is controversial. Based on the results of this study, the
current guidelines suggested by the American College of Chest Physicians
and the Scottish Guideline Network to limit DVT prophylaxis in varicose
vein surgery to those patients with risk factors for DVT appears appropriate.
Patients with multiple risk factors perhaps should also be considered for
more extended prophylaxis.
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